|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 PENNSYLVANIA AVENUE, NW, SOUTH BUILDING |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1581-12
|
||||||||
|
6. House ID# 306290000
|
TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Adrienne Morrell |
Date | 4/19/2018 4:13:00 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 1215, Protecting Access to Care Act (King) - medical liability reform
H.R. 1313, Preserving Employee Wellness Programs Act (Foxx) - employee wellness programs
S. 1625, FY 2018 Consolidated Appropriations Act (Royce) - funding for HHS programs and agencies, opioid initiatives, ACA risk corridors
H.R. 2422, Action for Dental Health Act (Kelly) - oral health services and education for underserved populations
H.R. 3759, RAISE Family Caregivers Act (Harper-Castor) - support for family caregivers
Regulatory Issues:
HIPAA administrative simplification issues, including standards for privacy, security, and electronic transactions and code sets (including ICD-10), identifiers including the health plan identifier, enforcement; cybersecurity; FEHBP enrollment data clearinghouse initiative, the enrollment reconciliation process, and a related OPM reimbursement factor for records that cannot be reconciled; issues relating to health insurance plan participation in FEHBP, including contract requirements; issues relating to similarly sized subscriber group (SSSG) and MLR requirements under the FEHBP; implementation of the health savings account provisions of the Medicare Act; issues related to Medicare Secondary Payer requirements; issues related to implementation of the National Health Information Infrastructure; electronic health records, personal health records, and similar technologies; issues relating to market consolidation; issues related to hospital consolidation; issues relating to quality improvement; issues relating to the national health data stewardship; issues relating to hospital outpatient measurement and reporting; prescription drug pricing; issues related to the collection of race and ethnicity data; issues related to medical loss ratios; reference pricing; review of rates for reasonableness; preexisting condition insurance plans; issues relating to antitrust; accountable care organizations; provider non-discrimination; coverage of preventive services; contraceptive coverage; pre-existing condition exclusions; lifetime and annual dollar limits on benefits; patient protections; grandfathered health plan provisions; issues relating to the annual fee on health insurance providers; health plan automatic enrollment requirements; issues related to qualified health plans including certification and rate filing templates; health insurance market rules; reinsurance, risk corridors, and risk adjustment; dependent coverage; summary of benefits and coverage disclosures; benefit and payment parameters; essential health benefits, actuarial value, and accreditation; issues related to fraud, waste, abuse, Stark/Anti-Kickback laws and regulations; issues related to supplemental products; issues related to HIPAA excepted benefits; issues related to short term limited duration products; issues related to the federally-facilitated marketplaces (i.e., Exchanges/formerly referred to as the web portal); issues related to business continuity in relation to pandemics or natural events (e.g., hurricane, tornado, etc.); issues related to association health plans; issues related to cost-sharing reductions (CSRs); issues related to the refundable credit for coverage under a qualified health plan; issues related to small employer group size; issues related to Certificate of Public Advantage; issues relating to veterans health care; issues relating to family caregivers; and other issues relating to health care reform implementation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Labor - Dept of (DOL), Treasury - Dept of, White House Office, Internal Revenue Service (IRS), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Callanan |
|
|
|
Gregory |
Gierer |
|
|
|
Jeanette |
Thornton |
|
|
|
Jay |
Perron |
|
|
|
Thomas |
Meyers |
|
|
|
Marilyn |
Tavenner |
|
|
|
Kathryn |
Gallagher |
|
|
|
Rhys |
Jones |
|
|
|
Adrienne |
Morrell |
|
|
|
Matthew |
Eyles |
|
|
|
Mark |
Hamelburg |
|
|
|
Katie |
Allen |
|
|
|
Adam |
Beck |
|
|
|
Christopher |
Anderson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S. 413, Improving Transparency and Accuracy in Medicare Part D Spending Act (Capito) -PDP/MA-PD payments on clean claims from pharmacies
S. 428, ACE Kids Act (Grassley) - coordinated care for children with complex medical conditions
S. 1016, CONNECT For Health Act (Schatz) - telehealth
S. 1169, Medicaid CARE Act (Durbin-Portman) - changes to Medicaid IMD exclusion
S. 1688, Empowering Medicare Seniors to Negotiate Drug Prices Act (Klobuchar) - Part D price negotiations
S. 1804, Medicare for All Act (Sanders) - single payer health system
S. 1827, Keep Kids Insurance Dependable and Secure Act (Hatch-Wyden) - federal CHIP funding
S. 1890, Chronic Kidney Disease Improvement in Research and Treatment and Medigap Access (Cardin) - Medigap coverage for beneficiaries with end-stage renal disease
S. 2027, Medicaid Third Party Liability Act (Portman) - Medicaid third party liability
S. 2227, EMPOWER Care Act (Portman-Cantwell) - Medicaid Money Follows the Person Demonstration
Draft Medicare Extenders Bill (Senate Finance Committee) - continuation of expiring Medicare provisions
H.R. 195, Extension of Continuing Appropriations Act - CHIP funding extension for 2018-2023 and related provisions
H.R. 849, Protecting Seniors Access to Medicare Act (Roe) - Independent Payment Advisory Board
H.R. 908, Medicare Advantage Quality Payment Relief Act (Kelly) - MA payment cap
H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act (Griffith) - PDP/MA-PD payments on clean claims from pharmacies
H.R. 1148, FAST Act (Griffith) - access to telehealth-eligible stroke services under Medicare
H.R. 1316, Prescription Drug Price Transparency Act (Collins) - PBM standards for MA and PDP plans
H.R. 1892, Bipartisan Budget Act (Larson) - permanent authorization of Medicare Advantage Special Needs Plans; MA chronic care reforms: telehealth, supplemental benefits, value-based insurance design, star ratings; changes to Medicare Part D coverage gap and related discounts; CHIP funding extension for 2024-2027; funding for Puerto Ricos Medicaid program
H.R. 1995, V-BID for Better Care Act (Black) - value-based insurance design in Medicare Advantage
H.R. 2556, CONNECT For Health Act (Black) - telehealth
H.R. 2644, Chronic Kidney Disease Improvement in Research and Treatment and Medigap Access (Marino) - Medigap coverage for beneficiaries with end-stage renal disease
H.R. 2687, Medicaid CARE Act (Foster-Fitzpatrick) - changes to Medicaid IMD exclusion
H.R. 3044, Supplemental Benefits for Chronically Ill Medicare Advantage Enrollees (Meehan)
H.R. 3168, Special Needs Plans (Tiberi-Levin) - SNP reauthorization
H.R. 3263, Medicare Independence at Home Model of Care (Burgess) - demonstration program
H.R. 3325, ACE Kids Act (Barton) - coordinated care for children with complex medical conditions
H.R. 3360, Telehealth Enhancement Act (Harper) - telehealth in Medicare
H.R. 3727, Increasing Telehealth Access in Medicare Act (Black) - telehealth in MA plans
H.R. 3921, HEALTHY KIDS Act (Burgess) - CHIP funding
Medicare Extenders Package (House Ways and Means Committee) - reauthorization of Special Needs Plans, telehealth, CMS authority to terminate MA contracts
Regulatory Issues:
Ongoing implementation issues for the Medicare Advantage (MA) and Medicare Part D prescription drug programs, including risk adjustment methodology, network adequacy and provider directories, encounter data and other data-related issues, and audit issues; bidding and payment issues (including MA rate assumptions, MA coding intensity, MA Secondary Payer issues, Part D reinsurance, Part D low income subsidies, Part D direct and indirect remuneration (DIR), and audits); proposed calendar year 2019 policy and technical regulation for MA and Part D; in-home health risk assessments; Medicare Medical Loss Ratio issues; implementation of sequestration under the Medicare Advantage and Part D programs; implications of the health insurer fee for MA and Part D plans; application process, audits to evaluate compliance with MA and Part D program rules, benefit design rules, enrollment rules, requirements for notice and denial forms, marketing materials review and approval, marketing activities, including conduct and compensation of brokers and agents and plan sponsor marketing staff; measurement and oversight of plan performance including Special Needs Plans (SNPs); quality measures, grievance and appeals processes, fraud and abuse compliance including training; contracting issues for Dual Eligible SNPs; Bipartisan Budget Act of 2018 changes to SNPs; Federal preemption of State authority under MA and Part D programs, Part D prescription drug event data reporting, Part D formulary rules, Part D pharmacy access standards, Part D coverage gap discount program, including employer group waiver plan (EGWP) issues, and other operational issues; issues raised by Part D coverage of new specialty drugs, the Part D non-interference policy and related issues (e.g., preferred pharmacy and any willing pharmacy requirements, standards for network pharmacy reimbursement, and policies regarding sponsor negotiation of pharmacy price concessions); CMS's proposed Part B drug demonstration program; Medication Therapy Management Program requirements and the Center for Medicare and Medicaid Innovation (CMMI) Demonstration; MA EGWP issues; CMMI's value-based insurance design (VBID) demonstration; Part D requirements for offering basic and enhanced alternative plans; MA and Part D systems issues affecting enrollment and disenrollment processing and payment and other operational issues; issues relating to MA and Part D Star Rating system including measures, the methodology for calculating ratings, and the role of the ratings for payment purposes; implementation of the Affordable Care Act (ACA) and the Bipartisan Budget Act of 2018 changes to the Part D coverage gap; functionality of the Medicare Personal Plan Finder and Drug Plan Finder; National Medicare Education Program; Medicare demonstration program on performance-based payments for physician groups; physician quality reporting initiative; issues relating to Medicare coverage policy and national coverage decisions; new payment system for physicians under MACRA, including implications for MA and Part D plans; Medicare clinical trials; Medicare/Medicaid integration for dual eligibles, including implementation of the Capitated Financial Alignment Demonstration and related issues (e.g., quality ratings); Medicaid managed care regulations and policies, including CMS' substantial revisions to the managed care regulations, mental health parity rules, the Medicaid managed care actuarial soundness standard, quality oversight, Medicaid and CHIP Payment and Access Commission (MACPAC), grievance and appeals processes, fraud and abuse compliance, beneficiary information requirements, treatment of Medicaid health plan member hospital days in the upper payment limit calculation; policies affecting State Medicaid funding, including block grants, the calculation of the federal medical assistance (federal matching) percentage (FMAP), and intergovernmental transfers (IGTs); coordination of benefits with state Medicaid programs; Medicaid prescription drug cost issues affecting Medicaid health plans including issues raised by Medicaid coverage of new specialty drugs; health plan-related Childrens Health Insurance Program (CHIP) issues, including eligibility and outreach issues and CHIP reauthorization; implementation of Medicaid changes made in Deficit Reduction Act of 2005, including Medicaid managed care organization provider tax issues; standards for electronic prescribing; implementation of Medicaid changes of interest to Medicaid health plans made in the ACA including Medicaid expansion, the managed care organization (MCO) prescription drug rebate provisions, minimum payments to primary care providers (PCPs), interactions between the Medicaid program and health insurance exchanges, and Medicaid and CHIP maintenance of effort (MOE) requirements; implications of the health insurer fee for Medicaid health plans; issues related to Medicaid Managed long-term care including home and community-based waiver services (HCBS); expanding the availability of Medicare Advantage and Medicaid health plan telemedicine programs; implications of the new non-discrimination rules for health plans participating in public programs; issues related to Medigap coverage; issues related to business continuity in relation to pandemics or natural events (e.g., hurricane, tornado, etc.); cybersecurity; provider directories; value-based insurance design models; Part D prescriber enrollment requirements; Part D recovery audit contractor programs; issues relating to enrollment of beneficiaries with ESRD into MA plans; socioeconomic status impacts on star ratings related to MA and Part D programs; and other issues relating to health care reform implementation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Callanan |
|
|
|
Jeanette |
Thornton |
|
|
|
Jay |
Perron |
|
|
|
Marilyn |
Tavenner |
|
|
|
Kathryn |
Gallagher |
|
|
|
Rhys |
Jones |
|
|
|
Adrienne |
Morrell |
|
|
|
Matthew |
Eyles |
|
|
|
Mark |
Hamelburg |
|
|
|
Katie |
Allen |
|
|
|
Christopher |
Anderson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Bipartisan Health Care Stabilization Act (Alexander-Murray) - funding for cost sharing reduction benefits, stabilization of individual market
Bipartisan Health Care Stabilization Act; updated version (Alexander-Walden-Collins-Costello) - funding for cost sharing reduction benefits and reinsurance, stabilization of individual market
S. 147, Obamacare Taxpayer Bailout Prevention Act (Rubio) - ACA risk corridors program
S. 581, Jessies Law (Manchin-Capito) - patient history of opioid use disorder
S. 1201, Health Care Options for All Act (McCaskill) - coverage options in bare counties
S. 1354, Individual Health Insurance Marketplace Improvement Act (Carper-Kaine) - individual market reinsurance fund, outreach and enrollment activities
S. 1462, Marketplace Certainty Act (Shaheen) - funding for cost-sharing reduction benefits
S. 1516, Coverage Across State Lines (Heller)
S. 1667, Protecting Consumers from Unreasonable Rates Act (Feinstein) - rate review
S. 1771, FY 2018 Labor-HHS Appropriations Act (Blunt) - risk corridors and other ACA issues, funding for HHS programs and agencies
S. 1835, Lower Premiums Through Reinsurance Act (Collins-Nelson) - invisible high risk pool and reinsurance programs
S. 1850, Legacy Act (Manchin-Capito) -- confidentiality of drug and alcohol treatment and prevention records
S. 1976, Increasing Access to Care Act (Scott) - copper plan
S. 1985, Protect Access to Birth Control Act (Murray) - coverage of contraceptive services
S. 2052, Healthcare Market Certainty and Mandate Relief Act (Hatch) - funding for cost sharing reduction benefits, HSA improvements, ACA individual mandate
S. 2241 (King) - fees on excepted benefits and standalone dental plans
S. 2303, Access to Independent Health Insurance Advisors Act (Isakson-Coons) - calculation of medical loss ratios
S. 2410, Chronic Disease Management Act (Thune) - flexibility for high-deductible health plans
H.R. 314, Health Care Choice Act (Blackburn) - selling insurance across state lines
H.R. 372, Competitive Health Insurance Reform Act (Gosar) - McCarran-Ferguson Act
H.R. 421, Allowing Greater Access to Safe and Effective Contraception Act (Love) - non-prescription contraceptives, HSA flexibility
H.R. 706, Plan Verification and Fairness Act (Blackburn) - verifying eligibility for special enrollment periods
H.R. 708, State Age Rating Flexibility Act (Buchson) - age rating bands
H.R. 710, Health Coverage State Flexibility Act (Flores) - grace period for premium payments
H.R. 1101, Small Business Health Fairness Act (Johnson) - association health plans
H.R. 1121, Pre-existing Conditions Protection Act (Walden) - protections for patients with pre-existing conditions
H.R. 1304, Self-Insurance Protection Act (Roe) - medical stop-loss insurance
H.R. 1409, Cancer Drug Parity Act (Lance) - coverage of oral anti-cancer drugs
H.R. 3354, FY 2018 Appropriations Act (Calvert) - risk corridors and other ACA issues, funding for HHS programs and agencies
H.R. 3358, FY 2018 Labor-HHS Appropriations Act (Cole) - risk corridors and other ACA issues, funding for HHS programs and agencies
H.R. 3450, Protecting Consumers from Unreasonable Rates Act (Schakowsky) - rate review
H.R. 3545, Overdose Prevention and Patient Safety Act (Murphy- Blumenauer) -- confidentiality of drug and alcohol treatment and prevention records
H.R. 3922, CHAMPION Act (Walden) - extension of federal CHIP funding, ACA grace periods, community health center funding
H.R. 3976, Access to Marketplace Insurance Act (Cramer) - third party payments
H.R. 4082, Protect Access to Birth Control Act (DeGette) - coverage of contraceptive services
H.R. 4200, Healthcare Market Certainty and Mandate Relief Act (Brady) - funding for cost sharing reduction benefits, HSA improvements
H.R. 4225 (Hudson) - fees on excepted benefits and standalone dental plans
H.R. 4575, Access to Independent Health Insurance Advisors Act (Long-Schrader) - calculation of medical loss ratios
H.R. 4666, Premium Relief Act (Costello) - Patient and State Stability Fund
H.R. 4695, Bipartisan Market Stabilization and Innovation Act (Schrader) - stabilization of individual market
H.R. 4978, Chronic Disease Management Act (Black) - flexibility for high-deductible health plans
Regulatory Issues:
Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; disability income insurance enrollment and awareness; issues related to encouraging impaired workers to stay in/return to the workforce; issues relating to the coordination of benefits between private health insurance plans and Medicaid; Medigap claims processing and crossover fees; Medigap cross-over claim issues, Medigap coverage, implementation of Medigap standardized plan offerings; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials, and other Medigap issues; fraud and abuse issues affecting public and private insurance coverage; issues relating to antitrust; implementation of the Mental Health Parity Act requirements; implementation of the 21st Century Cures Act requirements; summary of benefits and coverage disclosures; pre-existing condition insurance plans; accountable care organizations; coverage of preventive services; preexisting condition exclusions; lifetime and annual dollar limits on benefits; patient protections; grandfathered health plan provisions; dependent coverage; treatment of expatriate plans; issues related to all payor claims databases; issues related to association health plans; issues related to fraud, waste, abuse, Stark/Anti-Kickback laws and regulations, non-discriminatory wellness programs; issues related to supplemental products; issues relating to dental coverage; issues relating to proposals for single-payer and Medicare/Medicaid buy-in options; issues related to implementation of the Telephone Consumer Protection Act; issues relating to third party payment of premiums; issues related to cost-sharing reductions (CSRs); issues relating to the individual market; and other issues relating to health care reform implementation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Centers For Medicare and Medicaid Services (CMS), Treasury - Dept of, White House Office, Internal Revenue Service (IRS), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Callanan |
|
|
|
Gregory |
Gierer |
|
|
|
Jeanette |
Thornton |
|
|
|
Jay |
Perron |
|
|
|
Marilyn |
Tavenner |
|
|
|
Kathryn |
Gallagher |
|
|
|
Thomas |
Meyers |
|
|
|
Rhys |
Jones |
|
|
|
Adrienne |
Morrell |
|
|
|
Matthew |
Eyles |
|
|
|
Katie |
Allen |
|
|
|
Adam |
Beck |
|
|
|
Christopher |
Anderson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S. 297, Increasing Competition in Pharmaceuticals Act (Collins-McCaskill) - prescription drug costs
S. 974, CREATES Act (Leahy-Grassley) - access to generic drugs and biosimilars
S. 1115, Making Pharmaceutical Markets More Competitive Act (Collins-McCaskill) - accelerated approval of generic therapies
S. 1131, FAIR Drug Pricing Act (Baldwin-McCain) - transparency in prescription drug pricing
S. 2553, Know the Lowest Price Act (Stabenow) - information on drug prices
S. 2554, Patient Right to Know Drug Prices Act (Collins) - information on drug prices
H.R. 749, Lower Drug Costs Through Competition Act (Schrader-Bilirakis) - prescription drug costs
H.R. 1703, Medical Product Communication Act (Griffith) - off-label exchange of information
H.R. 2026, Pharmaceutical Information Exchange Act (Guthrie) - pre-approval health care economic information to payors
H.R. 2051, Fair Access for Safe and Timely Generics Act (McKinley-Welch) - access to generic drugs
H.R. 2212, CREATES Act (Marino-Cicilline) - access to generic drugs and biosimilars
H.R. 2439, FAIR Drug Pricing Act (Schakowsky) - transparency in prescription drug pricing
H.R. 2562, Making Pharmaceutical Markets More Competitive Act (Kelly) - accelerated approval of generic therapies
H.R. 2999, Patients' Access to Treatments Act (McKinley) - limiting cost sharing in specialty drug tiers
H.R. 5247, Right to Try Act (Fitzpatrick) - use of unapproved investigational drugs by patients with life-threatening conditions
Regulatory Issues:
Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics; issues relating to opioids; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Executive Office of the President (EOP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Callanan |
|
|
|
Jay |
Perron |
|
|
|
Marilyn |
Tavenner |
|
|
|
Kathryn |
Gallagher |
|
|
|
Rhys |
Jones |
|
|
|
Adrienne |
Morrell |
|
|
|
Matthew |
Eyles |
|
|
|
Katie |
Allen |
|
|
|
Mark |
Hamelburg |
|
|
|
Gregory |
Gierer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S. 28, Health Savings Account Expansion Act (Flake) - HSA improvements
S. 85, Restoring Access to Medications Act (Roberts) - paying for OTC products with HSA funds
S. 403, Health Savings Act (Hatch) - HSA and FSA improvements
S. 761, Health Care Options Act (Alexander) - using premiums for off-Exchange plans
S. 1859, Healthcare Tax Relief Act (Gardner) - suspension of ACA health insurance tax
S. 1978, Small Business and Family Health Tax Relief Act (Heitkamp) - suspension of ACA health insurance tax
H.R. 195, Extension of Continuing Appropriations Act - one-year suspension of ACA health insurance tax, two-year delay in ACA excise tax on employer-sponsored health plans
H.R. 246, Jobs and Premium Protection Act (Noem-Sinema) - repeal of ACA health insurance tax
H.R. 247, Health Savings Account Expansion Act (Brat) - HSA improvements
H.R. 394, Restoring Access to Medications Act (Jenkins) - paying for OTC products with HSA funds
H.R. 1175, Health Savings Act (Paulsen) - HSA and FSA improvements
H.R. 4616 (Nunes) - delay in ACA Cadillac tax
H.R. 4618 (Jenkins) - use of HSA funds for OTC medications
H.R. 4620, Protecting Families and Small Businesses Act (Noem) - relief from ACA health insurance tax
H.R. 4894, Harmful Tax Prevention Act (Noem) - relief from ACA health insurance tax
H.R. 5138, Bipartisan HSA Improvement Act (Kelly) - HSA changes
Regulatory Issues:
Annual insurer provider fees; issues concerning the patient-centered outcomes research fee; employer and individual coverage mandate; W-2 reporting requirements; health reimbursement accounts; deductibility limits for insurer compensation; health insurer and employer reporting of health coverage; issues related to implementation of health insurance tax; issues related to the refundable credit for coverage under a qualified health plan; issues related to coverage of chronic conditions in high deductible health plans; issues related to health savings accounts; issues related to the deductibility of employer-sponsored health coverage; issues related to qualified small employer health reimbursement accounts (QSEHRAs); issues related to implementation of the excise tax on high cost employer-sponsored health coverage; and other issues relating to health care reform implementation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Callanan |
|
|
|
Gregory |
Gierer |
|
|
|
Jeanette |
Thornton |
|
|
|
Jay |
Perron |
|
|
|
Marilyn |
Tavenner |
|
|
|
Kathryn |
Gallagher |
|
|
|
Adrienne |
Morrell |
|
|
|
Matthew |
Eyles |
|
|
|
Katie |
Allen |
|
|
|
Adam |
Beck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: https://www.ahip.org/about-us/board-of-directors/
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |